PTK787/ZK 222584 is an inhibitor of VEGFR family tyrosine kinases. The primary objective of
this study is to assess the safety of daily oral PTK787/ZK 222584 in combination with
paclitaxel infused every 21 days. Secondary objectives include pharmacokinetic assessment of
the impact of PTK787/ZK 222584 on paclitaxel metabolism and evaluation of tumor response to
the investigational treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Novartis Pharmaceuticals